Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Am Dent Assoc ; 145(2): 182-9, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24487610

ABSTRACT

BACKGROUND: The authors conducted a systematic review to assess the efficacy and safety of fluoride toothpaste use in children younger than 6 years. METHODS: The authors defined research questions to formulate a search strategy. They screened studies, extracted data and assessed risk of bias systematically. They conducted meta-analyses to determine the effects of brushing with fluoride toothpaste. RESULTS: Use of fluoride toothpaste brushing had a statistically significant effect on mean decayed, missing and filled primary tooth surfaces and decayed, missing and filled primary teeth for populations at high risk of developing caries (standard mean difference [95 percent confidence interval {CI}], -0.25 [-0.36 to -0.14] and -0.19 [-0.32 to -0.06], respectively). The effects of using different fluoride concentration toothpastes on caries varied. Study findings showed either a decrease in the odds of having fluorosis (odds ratio [OR] [95 percent CI] = 0.66 [0.48-0.90]) when the use of fluoride toothpaste was initiated after 24 months or no statistically significant difference (OR [95 percent CI] = 0.92 [0.71-1.18]). Beginning use after 12 or 14 months of age decreased the risk of fluorosis (OR = 0.70 [0.57-0.88]). CONCLUSIONS: Limited scientific evidence demonstrates that for children younger than 6 years, fluoride toothpaste use is effective in caries control. Ingesting pea-sized amounts or more can lead to mild fluorosis. Practical Implications. To minimize the risk of fluorosis in children while maximizing the caries-prevention benefit for all age groups, the appropriate amount of fluoride toothpaste should be used by all children regardless of age. Dentists should counsel caregivers by using oral description, visual aids and actual demonstration to help ensure that the appropriate amount of toothpaste is used.


Subject(s)
Cariostatic Agents/administration & dosage , Fluorides, Topical/administration & dosage , Safety , Toothpastes/chemistry , Cariostatic Agents/adverse effects , Child , Child, Preschool , DMF Index , Fluorides, Topical/adverse effects , Fluorosis, Dental/etiology , Humans , Infant , Toothbrushing
2.
J Am Dent Assoc ; 144(9): 1030-5, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23989842

ABSTRACT

BACKGROUND: The 2007 American Heart Association (AHA) guidelines for the prevention of infective endocarditis (IE) called for a major reduction in the number of patients recommended for antibiotic prophylaxis (AP) and redefined the dental procedures considered to put these patients at risk of acquiring the infection. The purpose of the authors' study was to determine the acceptance of these changes among and the impact of the changes on dentists and their patients. METHODS: The authors sent a survey to a random sample of 5,500 dentists in the United States. RESULTS: Ninety-five percent of the 878 respondents indicated that they saw patients who receive AP. More than 75 percent were either satisfied or very satisfied with the AHA guidelines, and the respondents indicated that they believed almost three-quarters of their patients also were pleased. Seventy percent of dentists, however, had patients who took antibiotics before a dental procedure even though the guidelines no longer recommend it. CONCLUSIONS: Acceptance of the 2007 guidelines appears to be high, but controversy remains. Additional scientific data are needed to resolve these issues. PRACTICAL IMPLICATIONS: The 2007 AHA guidelines have greatly simplified the identification of patients who need AP for dental procedures, given that, in general, far fewer people with cardiac abnormalities are considered to be at risk as a result of invasive procedures. Some physicians, however, continue to prescribe antibiotics for some patients whom the AHA no longer considers to need them. Patients also may choose to continue this practice themselves. There is ongoing controversy surrounding this common clinical question in dental practice, and the next guidelines from the AHA may change on the basis of data from future clinical studies.


Subject(s)
American Heart Association , Antibiotic Prophylaxis , Attitude of Health Personnel , Attitude to Health , Dentists/psychology , Guideline Adherence , Practice Guidelines as Topic , Adult , Aged , Dental Care , Endocarditis, Bacterial/prevention & control , Female , General Practice, Dental , Heart Diseases/complications , Humans , Male , Middle Aged , Mitral Valve Prolapse/complications , Personal Satisfaction , United States
4.
J Am Acad Orthop Surg ; 21(3): 180-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23457068

ABSTRACT

The Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures evidence-based clinical practice guideline was codeveloped by the American Academy of Orthopaedic Surgeons (AAOS) and the American Dental Association. This guideline replaces the previous AAOS Information Statement, "Antibiotic Prophylaxis in Bacteremia in Patients With Joint Replacement," published in 2009. Based on the best current evidence and a systematic review of published studies, three recommendations have been created to guide clinical practice in the prevention of orthopaedic implant infections in patients undergoing dental procedures. The first recommendation is graded as Limited; this recommendation proposes that the practitioner consider changing the long-standing practice of routinely prescribing prophylactic antibiotic for patients with orthopaedic implants who undergo dental procedures. The second, graded as Inconclusive, addresses the use of oral topical antimicrobials in the prevention of periprosthetic joint infections. The third recommendation, a Consensus statement, addresses the maintenance of good oral hygiene.


Subject(s)
Dental Implants , Oral Surgical Procedures/adverse effects , Prosthesis-Related Infections/prevention & control , Anti-Infective Agents/administration & dosage , Antibiotic Prophylaxis , Bacteremia/epidemiology , Evidence-Based Dentistry , Evidence-Based Medicine , Humans , Incidence , Index of Orthodontic Treatment Need , Oral Hygiene
5.
J Am Dent Assoc ; 142(11): 1243-51, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22041409

ABSTRACT

BACKGROUND: This narrative review of osteonecrosis of the jaw in patients with low bone mass receiving treatment with antiresorptive agents is based on an appraisal of the literature by an advisory committee of the American Dental Association Council on Scientific Affairs. It updates the committee's 2008 advisory statement. METHODS: The authors searched MEDLINE for literature published between May 2008 (the end date of the last search) and February 2011. RESULTS: This report contains recommendations based on the findings of the literature search and on expert opinion that relate to general dentistry; periodontal disease management; implant placement and maintenance; oral and maxillofacial surgery; endodontics; restorative dentistry and prosthodontics; orthodontics; and C-terminal telopeptide testing and drug holidays. CONCLUSIONS: The highest reliable estimate of antiresorptive agent-induced osteonecrosis of the jaw (ARONJ) prevalence is approximately 0.10 percent. Osteoporosis is responsible for considerable morbidity and mortality. Therefore, the benefit provided by antiresorptive therapy outweighs the low risk of developing osteonecrosis of the jaw. CLINICAL IMPLICATIONS: An oral health program consisting of sound hygiene practices and regular dental care may be the optimal approach for lowering ARONJ risk. No validated diagnostic technique exists to determine which patients are at increased risk of developing ARONJ. Discontinuing bisphosphonate therapy may not lower the risk but may have a negative effect on low-bone-mass-treatment outcomes.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention & control , Bone Density Conservation Agents/therapeutic use , Osteoporosis/drug therapy , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Biomarkers/blood , Bone Density Conservation Agents/adverse effects , Collagen Type I/blood , Denosumab , Dental Care for Chronically Ill , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Humans , Oral Hygiene , Oral Surgical Procedures , Osteoporosis/prevention & control , Patient Care Planning , Peptides/blood , RANK Ligand/antagonists & inhibitors , Risk Factors
6.
J Am Dent Assoc ; 140(10): 1228-36, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19797552

ABSTRACT

BACKGROUND: The authors conducted a study to determine concentrations of fluoride in infant formulas, and to estimate fluoride intake in infants consuming predominantly formula. The authors compared estimated fluoride ingestion with the tolerable upper limit and adequate intake level for fluoride recommended by the Institute of Medicine (IOM). METHODS: The authors analyzed fluoride concentrations of powdered and liquid formula concentrates and ready-to-feed formulas. They estimated the total fluoride ingested by infants by considering the fluoride content measured in both the infant formula and various concentrations of fluoridated water. They based consumption volumes on published recommendations. The authors compared estimates for fluoride ingestion with the upper tolerable limit and adequate intake level, which they calculated by using published infant growth charts. RESULTS: Fluoride concentrations of the different formulas were low and, if reconstituted with low-fluoride water, would not result in ingestion of fluoride at levels exceeding the IOM's upper tolerable limit. Some infants aged between birth and 6 months who consume powdered and liquid concentrate formulas reconstituted with water containing 1.0 part per million fluoride likely will exceed the upper tolerable limit of fluoride. CONCLUSIONS: When powdered or liquid concentrate infant formulas are the primary source of nutrition, some infants are likely to exceed the recommended fluoride upper limit if the formula is reconstituted with water containing 1.0 ppm fluoride. On the other hand, when the fluoride concentration in water used to reconstitute infant formulas is below 0.4 ppm, it is likely that infants between 6 and 12 months of age will be exposed to fluoride at levels below IOM's recommended adequate intake level.


Subject(s)
Fluorosis, Dental/etiology , Infant Formula , Body Mass Index , Female , Fluoridation/adverse effects , Fluorides/analysis , Food Analysis , Growth Charts , Humans , Infant , Infant Food/adverse effects , Infant Formula/chemistry , Male , No-Observed-Adverse-Effect Level , Risk Factors
7.
Brain Res ; 924(2): 133-40, 2002 Jan 11.
Article in English | MEDLINE | ID: mdl-11750898

ABSTRACT

The dementia in Alzheimer disease (AD) is usually attributed to widespread neuronal loss in conjunction with the pathologic hallmarks of intracellular neurofibrillary tangles and extracellular plaques containing amyloid (A beta) in fibrillar form. Recently it has been demonstrated that non-fibrillar assemblies of A beta possess electrophysiologic activity, with the corollary that they may produce dementia by disrupting neuronal signaling prior to cell death. We therefore examined the effects of soluble oligomers of A beta(1-42) on long-term potentiation (LTP) and long-term depression (LTD), two cellular models of memory, in the dentate gyrus of rat hippocampal slices. Compared with vehicle controls, slices pre-incubated 60 min in the presence of A beta-derived diffusible ligands (ADDLs) showed no differences in threshold intensity to evoke a synaptic response, slope of field excitatory post-synaptic potentials (EPSPs), or the input/output function. Tetanus-induced LTP and reversal of LTD were strongly inhibited in ADDLs-treated slices whereas LTD was unaffected. These data suggest that soluble non-fibrillar amyloid may contribute to the pathogenesis of AD both by impairing LTP/memory formation at the cellular level and by creating 'neuroplasticity imbalance' manifested by unopposed LTD in the setting of impaired capacity for neural repair via reversal of LTD or LTP.


Subject(s)
Amyloid beta-Peptides/pharmacology , Dentate Gyrus/physiology , Long-Term Potentiation/drug effects , Neural Inhibition/drug effects , Peptide Fragments/pharmacology , Animals , Excitatory Postsynaptic Potentials/drug effects , Female , Male , Neuronal Plasticity/drug effects , Rats , Rats, Sprague-Dawley , Solubility , Synapses/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...